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     The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) 
estimate globally that 1.9 million children under the age of five years old die annually as 
consequence of diarrhea. Increasing need for hospitalization, which has negative effects on 
health care sectors, in addition to mortality incidences mark diarrheal related diseases a growing 
burden on both health care sectors and the global economy. Introducing novel measures to 
control and avert the spread of diarrheal disease are of paramount importance. Diarrhea is the 
main symptom in Acute gastroenteritis (AGE) and according to the United States' National 
Outbreak Reporting System (NORS), viral agents are the dominant precursors of epidemic AGE 
outbreaks. More than 90% of humans' acute non-bacterial gastroenteritis breakouts worldwide is 
caused by Noroviruses (NoVs). NoVs of the Caliciviridae family are none enveloped, positive 
sense, single stranded RNA virus, noncultivable in cell culture, containing three open reading 
frames (ORF). Expressing NoVs ORF2 in a baculovirus expression system produces empty 
virus-like particles (VLPs). These VLPs are very similar to the native virus in terms of 
morphology and antigenicity, yet lacking the genetic material essential for infectivity, making 
the VLPs a superb candidate for vaccine development. By comparing the capsid sequence of 
three different NoVs GII.4 strains, consensus GII.4 VLPs were produced as a potential vaccine 
with the goal of providing a broader protection against AGE. The main objective of this study is 
to understand the structural behavior of NoVs Consensus GII.4 VLPs, which is to be used as a 
vaccine. A complement of biophysical techniques has been employed to characterize the 
physical stability of Noroviruses Consensus GII.4 virus-like particles (VLPs) as a function of 
temperature and pH. The VLPs' physical stability are characterized by different spectroscopic 
techniques and the resulting data are used to construct empirical phase diagrams (EPDs) 
projecting the entire data set in the form of a colored image. These EPDs are used in the 
development of excipient screening assays to identify potential stabilizers of the VLPs in 
solution. The identified stabilizers are then subjected to further screening using fluorescence 
analysis to determine their optimal concentrations and use in combination. The generated data 
are used to construct binding isotherms for Consensus GII.4 VLP and aluminum salt adjuvants 
(Alhydrogel® and Adjuphos®). Binding isotherms were also generated for Norwalk VLP (a 
previously studied vaccine candidate) and aluminum salt adjuvants. Front Face Fluorescence 
Spectroscopy is used to evaluate the structural changes associated with Consensus GII.4 and 
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        In 2008 Black RE, et al estimated that around 1.3 million of the world's children 
under 5 years old dies from diarrhea.1 Liu, L., et al 2012 in a systemic analysis showed 
that 9.9 % of children deaths per year are a result of diarrhea.2 The (WHO) World Health 
Organization and the United Nations Children's Fund (UNICEF) project that 1.9 million 
worldwide deaths of the same age group are related to diarrheal diseases. In comparison 
to older estimates of 2.5 million deaths related to diarrhea in the 1990s, the above 
mentioned projections signal an improvement in lowering mortality rates of diarrheal 
related diseases.3 However, global diarrheal morbidity comparisons between 1990 and 
2013 show much less progress, with an increasing need for hospitalization and negative 
effects on economies.4 These deaths and disease incidences are a growing burden on 
health care sectors as well as the global economy.5 It is of great importance to introduce  
new measures to control and prevent the spread of diarrheal disease. 
  
        Acute gastroenteritis (AGE) is a globally prominent cause of illness with significant 
morbidity and mortality.6 High incidences of morbidity and patient hospitalization 
demonstrate the impact of the illness in developed countries with AGE outbreaks.7 AGE 
is characterized by acute diarrheal episodes in the presence or absence of vomiting. This 
gastrointestinal (GI) upset is mostly a result of microbial infection. Microbial agents, 
(viral, bacterial and protozoal), infect the GI primarily through two major mechanisms, 
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either multiplication in the intestine or by toxin production.8 The United States' National 
Outbreak Reporting System (NORS) indicated that viral agents are the dominant 
precursors of epidemic AGE outbreaks. Until recently rotavirus was the leading cause of 
AGE in the United States, and it was the main antagonist in the battle against AGE. 
However, the introduction of successful vaccination products has significantly lowered 
the incidences of Rotaviruses' related AGE, consequently lowering its risk. The time 
declining rates in rotavirus associated AGE were clinically observed was associated with 
a rise in AGE outbreaks of a different virus pathogen, designated Norovirus.9-13 
 
       Noroviruses (NoVs) cause over 90% (23 million cases/ year in the U.S) of acute non-
bacterial gastroenteritis breakouts worldwide in humans. This illness, spread through an 
oral-fecal route, affects people of all ages in many life setting (such as schools, retirement 
homes, cruise ships, military bases, etc). Symptoms such as Vomiting, watery diarrhea, 
and abdominal pain are usually seen after 15-48 hrs of infection with the virus, and they 
usually last for 12-60 hrs. Although these symptoms are considered to be short-lived and 
self-contained, they can be life threatening in geriatric and pediatric population as well as 
in immunocompromised individuals. Only 10 virions are needed to cause infection in a 
healthy person, which explains the high prevalence of the disease. Noroviruses (NoVs), a 
major gastrointestinal pathogen, are the primary cause of AGE globally accounting for 
approximately 20% of reported cases.14 In 1968 an outbreak occurred in Norwalk, Ohio 
affecting half of an elementary school's teachers and students with AGE. The culprit 
behind this epidemic was recognized as a virus and was assigned the name Norwalk virus 
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(NV). 15,16 Although visualized in 1972, the fact that NV is noncultivable in cell culture 
hindered its proper classification until 1990. Xi Jin, et al completed a successful genomic 
characterization of NV and molecular cloning confirmed the classification of NV as a 
member of the Caliciviridae family.17 NV And Norwalk-Like viruses (NLVs), referred to 
currently as NoVs, constitute a 27-38 nm particle, nonenveloped, positive sense 
polyadenylated, single stranded RNA virus of around 7,500 nucleotides that contains 
three open reading frames (ORF). 18-20 The longest NoVs ORF, ORF1 encodes 
nonstructural proteins that are imunoreactive in hosts. ORF2 expression in baculovirus 
infected insect cells yields a protein capsids (VP1) of 58 kD that self-assemble into virus 
like particles (VLPs). ORF3 encodes a minor structural protein (VP2) of 22.5 kD that is 
essential for enhancing the expression and conformation of  VP1.20, 21,23 Noroviruses are 
classified based on their VP1 into five major genogroups GI-GV. It is believed that 
genogroups GI, GII and GIV are responsible for human infections. Evidence collected in 
the past 15 years implicate the GII genogroup as a worldwide prevailing cause of 
sporadic and epidemic AGE. Most genogroups, including GII, are subdivided based on 
the amino acid sequences of VP1 into different genoclusters or genotypes. Genogroup II 
(GII) can be divided into more than 20 genotypes. GII genotype 4 (GII.4) is worldwide 
the major cause of human AGE outbreaks. GII.4 strains evolution with time is behind 
outbreaks recurrence and presents a major obstacle in implementing intervention and 
deterrence measures. GII.4 evolves through alteration of the amino acid sequence of 
VP1.22-26 NoVs cannot be cultivated in simple cell culture lines; also, no animal model to 
study the infectivity exists. These problems have hindered the development of an 
effective vaccine in the past. 
 4 
        Expressing NoVs ORF2 in a baculovirus expression system produces empty VLPs 
that self-assemble into a T=3 Icosahedral structure. Although these VLPs are very similar 
to the native virus in terms of morphology and antigenicity, they lack the genetic material 
essential for infectivity this has suggested the use of NoVs VLPs as a potential vaccine 
candidate. This protein complex (VLP) is made of 180 monomers that form a 90 dimer 
arch-like structure. The major component of this capsid is predominantly composed of 
VP1 and a few copies of a minor capsid protein (VP2). VP1 consists two domains, a shell 
domain (S-domain) and a protruding domain (P-domain). The S-domain is essential for 
the formation of the icosahedral structure while the P-domain, which is composed of two 
subdomains (P1) and (P2), binds to cellular specific receptors and is considered to be the 
antigenic part of the system. This antigenicity is limited by the high amino acid sequence 
variability of the VP1-P2 domain among strains of the same genocluster. This is the 
reason why protection from illness is not necessarily achieved after first time exposure. 
NoVs are phylogenetically subdivided into five genogroups and further subdivided into 
many genoclusters with GII.4 as the major source of global outbreaks. By comparing the 
capsid sequence of three different GII.4 strains, Houston, DenHaag89 and Yerseke38, 
NoVs consensus GII.4 VLPs were produced as a potential vaccine with the goal of 
providing a broader protection against AGE.26-30  
        The main objective of this study is to understand the structural behavior of a 
promising macromolecular entity, NoVs Consensus GII.4 VLPs, which is to be used as a 
vaccine. Characterization of the physical stability of macromolecules is one of the crucial 
steps in the preformulation and formulation development of safe and efficacious 
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vaccines. To achieve this goal, a complement of biophysical techniques has been 
employed to characterize the physical stability of Noroviruses Consensus GII.4 virus-like 
particles (VLPs) as a function of temperature and pH. The VLPs' physical stability are 
characterized by different spectroscopic techniques such as intrinsic and extrinsic 
fluorescence, circular dichroism, and static light scattering. The resulting data are used to 
construct empirical phase diagrams (EPDs) that are used to visualize the entire data set in 
the form of a colored image. These EPDs were then employed for the development of 
excipient screening assays to identify potential stabilizers of the VLPs in solution. A 
library of potential excipients was then screened for compounds that prevent the solution 
aggregation of the potential vaccines under stress conditions of temperature and pH. The 
identified stabilizers are then subjected to further screening to determine their optimal 
concentrations and use in combination. The effect of the stabilizers on the conformation 
of those potential vaccines is determined using fluorescence or CD analysis. The results 
obtained from the above mentioned experiments facilitated the construction of binding 
isotherms for Consensus GII.4 VLP as well as a previous studied vaccine candidate 
Norwalk VLP to aluminum salt adjuvants (Alhydrogel® and Adjuphos®). The structural 
changes associated with Consensus GII.4 and Norwalk VLPs when bound to aluminum 





Section - B 
Biophysical Characterization and stabilization of Consensus G11.4-VLP: 
 
Materials and Methods: 
 
Consensus GII.4 VLPs expression and purification: 
 
        By the alignment of the amino acid sequences of VLP capsid proteins for three 
NoVs GII.4, Houston/TCH186/2002/US (ABY27560), Yerseke38/ 2006/NL 
(ABL74391), and DenHaag89/2006/NL (ABL74395), the consensus GII.4 VLP amino 
acid sequence was designed. Consensus GII.4 sequence was encoded in a synthetic DNA 
fragment optimized for Sf9 (Spodoptera frugiperda) cells. Sf9 cells were supplied by via 
GeneArt at Regensburg, Germany for the purpose of developing a recombinant 
baculovirus to express the consensus GII.4 VLPs. of the DNA encoding the GII.4 
consensus VLPs was used to infect Sf9 cells and the supernatant was collected after 5 
days of infection. A proprietary process employing multiple orthogonal chromatography 
and ultrafiltration/diafiltration operations was used to yield VLPs with greater than 
99%purity.31 
 Sample preparation:  
 
        Recombinantly expressed Consensus G11.4 VLPs (Lot number Ligo 277.003.1, 
1.4mg/ml) were provided by Ligocyte Pharmaceuticals a liquid form at 4oC. All 
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chemicals were purchased from either Fisher Scientific (Pittsburgh, PA) or Sigma (St. 
Louis, MO) and were of analytical grade. 
 
        The VLPs were dialyzed overnight at 4oC against 20 mM Citrate Phosphate buffer 
containing 150 mM NaCl at different pH values ranging from 3-8 at one pH unit 
intervals. The buffer exchange was done using Spectra/pro molecular porous membrane 
tubes (Spectrum Lab, Rancho Dominguez, CA) with a MWCO (molecular weight cut-
off) of 15 kD. The protein concentrations of the VLPs were determined by measuring the 
absorbance at 280 nm using an extinction coefficient of 0.921 ml mg-1 cm-1 (obtained 
from the Protparam program in the Expasy server), and the amino acid sequence was 
provided by LigoCyte (Figure 1). The CD studies were performed at a protein 
concentration of 0.22 mg/ml. For all other studies a protein concentration of 0.055 mg/ml 




Far-UV Circular Dichroism (CD) Spectroscopy:  
        The spectral measurements were performed using a Jasco J-810 spectropolarimeter 
(Tokyo, Japan) with a six-position cell holder attached to a Peltier temperature controller. 
The CD measurements were performed at a scan rate of 20nm/min over a wavelength 
range of 200-260 nm with a two second response period and an accumulation of three 
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using 0.1 cm path-length cuvettes. Thermal unfolding of the VLPs was monitored at 208 
nm over a temperature range of 10-85°C at 2.5°C intervals with a temperature ramp rate 
of 15°C /hour.  
 
Intrinsic Tryptophan Fluorescence Spectroscopy and Static Light Scattering (SLS):  
 
  The intrinsic tryptophan fluorescence and static light scattering data were 
acquired using a PTI (Photon Technology International) Quantamaster 
spectrofluorometer (Birmingham, NJ) equipped with a turreted four-position peltier-
controlled cell holder. The excitation wavelength was set at 295 nm (> 95% Trp 
emission) and tryptophan emission spectra were acquired at wavelengths ranging from 
310-400 nm with a scan rate of 1 nm/sec. The excitation and emission slit width were set 
at 4 nm for both. Light scattering spectra were recorded at 295 nm by using a second 
photomultiplier positioned at 180° to the emission detector, and the slit width was set at 1 
nm. A temperature ramp of 10-85 °C was used with spectra obtained at intervals of 2.5°C 
with a three-minute equilibrium period between acquisitions. Buffer base lines were 
subtracted from each spectrum prior to data analysis. Data was analyzed using Fleix™ 
(PTI) and Microcal Origin 7.0 software. The peak positions and fluorescence intensity 
changes were obtained using a “center of spectral mass” method. Thus, the reported 
values are 10-12 nm higher than the actual values and do not correspond to actual peak 
positions, but accurately reflect changes in peak position values.  
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Extrinsic (ANS) Fluorescence Spectroscopy:  
 
        8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic fluorescent probe 
to determine surface-exposed hydrophobic patches during the thermal unfolding process 
of the VLPs. Samples prepared by mixing a 15-fold molar excess of ANS to the VLPs 
were excited at 385 nm and the emission spectra were acquired from 425-550 nm with a 
scan rate of 1nm/sec using the same spectrofluorometer described above. Emission 
spectra were acquired over a temperature range of 10-85 C° at 2.5 C° intervals using a 3 
min equilibrium period. Buffer base lines were subtracted from each spectrum prior to 
data analysis. The methods used for the analysis of ANS spectra were similar to those 
employed in the analysis of the intrinsic fluorescence data.  
 
Empirical Phase Diagram (EPD):  
 
        An empirical phase diagram was created employing data generated from intrinsic 
tryptophan fluorescence intensity changes and peak position shifts, extrinsic ANS 
fluorescence intensity changes, CD ellipticity values at 208 nm and static light scattering. 
Briefly, the data is represented as a vector field in a temperature and pH plane, from 
which a density matrix is generated. Eigenvalues and eigenvectors are calculated based 
on this density matrix. Eigenvectors corresponding to the three largest eigenvalues are 
used to transform the vector field into a three dimensional coordinate system, which is 
then represented as a color map. The dominant eigenvalues are assigned the colors red, 
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green and blue. The goal of this technique is to detect the changes in color, which present 
a qualitative picture of the transitional states in the protein. The phase diagram was 
generated using Matlab software (Mathworks, Inc., Natick, MA).32,33 
 
Excipient Screening Method Development: 
 
        Based on the results acquired by the above mentioned techniques, a high throughput 
aggregation assay was developed by monitoring the scattering of 0.1 mg/ml Consensus 
VLP at 350 nm (in a Cary 100 UV-Visible Spectrophotometer) over a period of 1 hr at 
60oC in 20 mM Histidine buffer, pH 6.5 containing 150 mM NaCl. A library of Generally 
Regarded As Safe (GRAS) excipients were then screened to detect potential stabilizers. 
The potential candidates were established based on their abilities to inhibit VLPs 
aggregation. The percentage of inhibition of aggregation in presence of excipients is 
calculated using the following equation: 
 
                         A350VLP alone-A350VLPs+excipient(s) 
% inhibition of Aggregation =            -----------------------------------------------    * 100 
                  A350VLP alone                            
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where A350VLP alone and A350VLP+excipient is the OD350 values at 1 h of the Consensus VLP in 




Far-UV Circular Dichroism Spectroscopy: 
 
        Changes in the secondary structure of Consensus GII.4 VLPs were followed by 
monitoring the changes in CD spectra across pH intervals ranging from 3-8, and a 
temperature gradient of 10-85 oC.  Figure 2A shows The CD spectra obtained at 10 oC for 
the studied pH intervals. All pH ranges display a single minimum around 208 nm and a 
detectable transition (shoulder) at 230 nm.  Figure 2B shows the effect of temperature on 
consensuses GII.4 VLPs secondary structure. The thermal denaturation acquired by CD 
melts indicate loss of secondary structure at different pH intervals. At pH 3, the CD melt 
of the consensus VLP reveals a thermal transition (Tm) at 73 oC. At pH 4 and 5, Tms 
were observed to be at 75 oC; whereas at pH 6 a 79 oC was obtained. Thermal transitions 
were not resolved for pH 7 and 8, where no marked transitions were detected (Table 1).  
Intrinsic Fluorescence Spectroscopy: 
 
        Tertiary structure conformational alterations were monitored by following the 
changes in both Tryptophan peak positions and Tryptophan fluorescence intensity as a 
function of temperature and pH (Figure 3A and 3B). Tryptophan residues buried in the 
hydrophobic core are seen to emit absorbed light at a maximum of 330. As the 
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macromolecule denaturates thermally the buried tryptophan residues will be more 
exposed to a hydrophilic (aqueous) environment as the protein unfolds. This hydrophilic 
exposure will shift the peak position to higher weave lengths, known as a red shift. This 
red shift can act as an indicator for the loss tertiary structure as the macromolecule 
unfolds. Figure 3A shows results for the pH range of 3 to 8 with the earliest transitions 
having Tms of 55 oC and 57 oC at pH. 3 and 8 respectively. At pH 5 and 6 the VLP resists 
unfolding with late transitions and Tms of around 64 oC. In contrast, at pH 4 and 7 the 
consensus VLPs displayed similarity in both transition and Tms (61 oC). Alteration to the 
tertiary structure can also be monitored using the temperature-dependent tryptophan 
fluorescence intensity changes (figure 3B). At pH 5 and 6, consensus VLPs show a 
transition onset at 60 oC. The onset of transitions for both pH 3 and pH 4 is at 55 oC and 
57 oC, respectfully. A broader transition is observed for both pH 7 and pH 8 which starts 
at around 55 oC. 
Static Light Scattering: 
 
        The aggregation behavior of the consensus GII.4 VLP was studied by monitoring 
static light scattering (SLS) data at 295 nm (figure 4). The onset and extent of 
aggregation are shown to be pH dependent, with both pH 7 and 8 displaying different 
aggregation profiles than the rest of the pH values. The extent of aggregation is seen to be 
maximum at pH 3 with an aggregation onset of 55 oC, whereas the aggregation onset for 
pH values of 4, 5 and 6 are 58, 56, and 62 oC respectively (Table 3).  
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Extrinsic Fluorescence Spectroscopy: 
 
         The changes in the fluorescence intensity of ANS bound to the VLPs as a function 
of pH and temperature are shown in Figure 5. At all pH values, the fluorescence intensity 
is initially high at low temperatures and then gradually decreases with some sharp 
transitions. As evident from the figure, Consensus VLPs show a single transition around 
55oC at pH 3, but at pH 6 and 7 the VLPs exhibit two distinct transitions, a first transition 
around 25-30oC and a second one around 63-67oC, respectively. Double transitions also 
occur at pH 8; however, the minor transition occurs at a higher temperature (at 50oC). At 
pH 4 and 5, the first transition is barely visible. 
 
Empirical Phase diagram (EPD): 
 
         An empirical phase diagram was constructed (Figure 6) using the data generated 
from CD melts, intrinsic tryptophan fluorescence intensity changes, changes in the 
tryptophan emission maxima, ANS fluorescence intensity changes and static light 
scattering as a function of pH and temperature. Several phases in the EPD are apparent 
and marked as regions P1-P7. Regions of uniform color indicate defined structural states 







 Aggregation was one of the most obvious mechanisms of consensus GII.4 VLP 
degradation and therefore an aggregation based turbidity assay was developed to screen 
for potential stabilizers.   Based on the data generated using the above-mentioned 
techniques, a general idea about the pH and temperature boundaries at which the VLP is 
most stable is established. An aggregation-based assay to screen a library of Generally 
Regarded As Safe (GRAS) excipients that might be used to increase VLP stability was 
developed. Experiments were carried out in histidine buffer (20 mM Histidine at pH 6.5 
containing 150 mM NaCl). Figures 7A and 7B show representative aggregation profiles 
of the Consensus GII.4 VLP in the absence and presence of selected excipients, where the 
aggregation of the VLP is inhibited or accelerated over a period of 1 hour. The 
percentage of inhibition of aggregation is calculated from the equation described in the 
materials and methods section.   
         From the data (Table 4), it is evident that sodium citrate (0.2M), trehalose (20%), 
dextrose (20%), glycerol (15%), lysine (0.3M), sucrose (20%) and mannitol (10%) inhibit 
the aggregation of the VLPs by more than 90%. Albumin, ascorbic acid and gelatin 
caused immediate turbidity when added to the VLP solution and thus could not be used in 
this assay. Some other excipients (e.g. glutamic acid, glycine and malic acid) also showed 
promising results; however, the excipients which showed more than 90% protection of 
aggregation were selected to further monitor the potential conformational changes 
associated with the VLP as a function of temperature. Although sodium citrate and lysine 
were good inhibitory candidates, they decreased the Tm of the peak position shift (data 
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not shown). Therefore, glycerol, sucrose and mannitol at different concentrations and 
combinations were examined for use in a preliminary formulation of the VLP as a result 
of both aggregation inhibition and enhanced conformational stability.  
Optimization of Excipient Concentrations and Combinations: 
 
  Promising candidates for VLP stabilization were chosen based on the preliminary 
screening assays described above. The optimal concentration of these potential stabilizers 
and their influence on VLP conformational stability were determined. The goal of this 
approach was to find an optimized recipe that will suppress Consensus GII.4 VLP 
structural deformation to a maximum. To achieve this, conformational changes of the 
VLP (0.055mg/ml) were monitored in histidine buffer (20mM Histidine buffer, pH 6.5, 
150 mM NaCl) by using intrinsic tryptophan fluorescence spectroscopy. Red shifts in the 
tryptophan emission maxima indicate increased unfolding (destabilization) of proteins in 
the VLP. The goal is to delay such shifts to a higher temperature (higher Tm). Figures 8A 
and 8B show plots of tryptophan peak position changes as a function of temperature of 
Consensus VLP in the presence of different concentrations and combinations of selected 
excipients. Table 5 shows the shifts in the Tm values of Consensus VLP in presence of the 
excipients (at different combinations and concentrations). The maximum change in the 
midpoint of the thermal transition (Tm) was seen with the combination of 10% sucrose 
and 15% mannitol (Tm shifts from 65.5 °C to 69.27 °C). 20% mannitol is the second best 
candidate and increased the Tm value by 2.9°C. Also, an additive effect is seen when 
using the combination of 10% sucrose and 10% mannitol (Tm shifts of +2.5 °C). Other 
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excipients alone or in combination showed minimal shifts or no shifts at all in the Tm 
values. 
 
        Discussion: 
 
        The physiochemical properties of Consensus GII.4 VLPs were examined using 
multiple biophysical techniques to characterize the stability of the macromolecule 
complex as a function of pH and temperature. Circular dichroism (CD) studies performed 
on the VLPs provided insight into the protein’s secondary structure. CD spectra obtained 
at 10 oC at different pH intervals showed a single minimum around 208 nm and a lassei 
transition (shoulder) at 230 nm, suggesting a class II beta-protein (single minimum 
208nm) and a type I beta turn conformation (shoulder at 230nm), a conformation adapted 
by many compact macromolecules (figure 2A).34-37In comparison, Ausar, SF, et al38 
study of a NV vaccine also found ClassII beta-protein in this vaccine candidate. CD 
Temperature perturbation studies show in figure 2B a loss in secondary structure for the 
VLPs at pH intervals 3-6. Over these ranges the sharp thermal transitions is clear 
evidence for the unfolding of the macromolecule when it exceeds 70 oC with pH 3 
showing the earliest onset and pH 6 as the least. This is in contrast to data suggesting 
Norwalk VLPs are more stable in an acidic environment. This acid stability presumably 
reflects viral resilience to the pH.39 Transition midpoint (Tm) values for the Consensus 
GII.4 VLP were calculated across the different pH conditions tested finding the VLP to 
be most resistance to temperature induced unfolding at pH 6. However, the pH from 7 to 
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8 showed no marked transitions. In comparison, Ausar, SF, et al, suggested that the NV 
VLPs capsid undergoes disruption at basic pH conditions, a phenomenon observed by 
White et al, as well.38,39 This may indicate that Consensus VLPs behave similarly in basic 
pH conditions, explaining the absence of any phase transition in pH 7 and 8.  
        According to the amino acid sequence shown in Figure 1, Consensus GII.4 VLP has 
6 tryptophan residues. Fluorescence studies of tryptophan peak position changes (figure3) 
illustrate the effect of pH and temperature on the tertiary structure of Consensus VLPs. 
Shifts in peak position from lower to higher wavelengths (red shift) are a clear indication 
of the change in polarity of the environment surrounding tryptophan residues. Tryptophan 
residues emitting light at wavelength values close to 330nm suggest tryptophans that are 
on average buried in apolar regions of the protein. Changes in environmental polarity 
toward hydrophilicity as a result of structural perturbation will yield a red shift in peak 
position as seen in figure 3A. The earliest red shift is demonstrated in pH ranges 3 and 8, 
suggesting that Consensus VLPs tertiary structure is most fragile at those pH conditions. 
The most resistant to tertiary structure dismantling are seen with pH conditions 5 and 6, 
where the Tm for both is around 64 oC (Table 3), corroborating the results obtained with 
CD. Alterations in the tertiary structure were further studied by monitoring tryptophan 
fluorescence intensity changes (figure 2B). The delayed onset displayed in pH conditions 
5 and 6 supports fluorescence peak position data discussed above. Also, tryptophan weak 
fluorescence intensity changes observed at pH 7 and 8 are evidence for disruption of 
consensus VLP capsid in basic pH conditions.41 
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              ANS (8-Anilino-1-naphthalene sulfonate) is a hydrophobic probe used to 
monitor the presence of accessible hydrophobic patches in a protein. The fluorescence 
intensity of ANS is very weak in aqueous solutions, but when bound to hydrophobic 
surfaces (such as in structurally disrupted proteins), the ANS fluorescence intensity 
increases drastically.  Exploiting this phenomena, more information regarding the 
protein's tertiary structure conformation is attained. In Figure 5, a greater intensity 
observed in all pH ranges at 10oC indicate ANS bound to hydrophobic regions of the 
macromolecule complex. A single early transition observed at pH 3 supporting previous 
results indicating the instability of NV VLP at this pH. At pH 4 two transitions are 
displayed. First, a minor transition starting at 26oC and a second at 65oC. Similar 
transitions are also observed at pH 5. More pronounced transitions are detected at pH 6 
and 7 with an initial transition at around 30oC and a second near 62oC. The early 
transition observed in pH intervals 4-7 are probably a result of the unfolding of one of the 
two domains on the VLPs capsid. A similar result was seen in NV VLPs' Ausar, SF, et al 
38 study.  
          Data obtained from Static Light Scattering showed that both the onset temperature 
and extent of aggregation are pH dependent (Figure 4). The highest extent of aggregation 
is seen in pH 3 with an early onset, backing up our initial estimate of the instability in this 
pH range. Both pH 4 and 5 displayed similarity in onset temperature; however, pH 5 
shows a different behavior evinced by the lag in the intensity curve. This may be 
attributed to a resistance to temperature induced aggregation. The latest onset is observed 
at pH 6, supportive of our previous data in that the maximum resistance to structural 
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conformational changes for Consensus GII.4 VLPs occurs under pH 5-6 conditions. The 
descending curves (figure 4) for pH conditions 7 and 8 may indicate a sudden 
precipitation of the VLPs at the onset temperature (Table 3), more evidence of instability 
of the VLPs in basic pH conditions.   
        The construction of the empirical phase diagram (EPD) illustrates a variety of 
alterations in the consensus GII.4 VLPs physical state (Figure 6). The changes in the 
conformational and colloidal stabilities as a function of pH and temperature was 
qualitatively described by changes in color. Throughout the EPD, the different 
conformational states the VLP adopts are depicted over different regions (labeled from 
P1 to P7). The region in greenish yellow (P1 and P4) are the regions of maximum 
stability in which the VLP remains in its native, folded conformation. Regions P3 and P5 
colored in light green are the regions where the VLP exhibits perturbed tertiary structure. 
Regions labeled as P6 may reflect molten globule-like states of the VLPs. Phases P2 and 
P7 are the regions of minimum stability with extensively aggregated and perturbed 
secondary and tertiary structures.  The VLP seems to be extensively unfolded in Phase 
P2. 
       The aggregation behavior obtained from excipient screening assays (Table 4) found 
that amino acid, sugars, and carbohydrates stabilize consensus GII.4 VLPs; similar results 
were demonstrated by Kissmann J, et al.40 Exclusion of lysine and sodium citrate from 
further investigation is due to their negative effect on the conformational stability of 
consensus GII.4 VLPs as shown by tryptophan fluorescence spectroscopy (data not 
shown). Osmolytes like trehalose, sucrose, and glycerol are known to stabilize 
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microorganisms naturally in stressful conditions; glycerol presumably enhances the 
stability by preferential hydration of the native state. Sucrose and terhalose, at elevated 
concentrations presumably also stabilize liquid formulations through a preferential 
hydration mechanism as well as hydrogen bond interactions. 41-43,45 Mannitol, often used 
as a bulking agent is also known to often in stabilize proteins, but in combination with 
sucrose are often found to be beneficial in stabilizing lyophilized formulations.46 
Glycerol, Sucrose, and mannitol displayed the most favorable outcome in both inhibition 
of aggregation and increasing Tm values. Thus they were chosen as promising candidate 
to be used in different combinations to enhance the stability of consensus GII.4 VLPs.  
        Using different excipient combination to achieve the most favorable outcome in 
delaying conformational alteration through increasing the Tm, value of consensus GII.4 
VLPs are displayed in figure 8. Sucrose at high concentrations (15% and 20 %) shows 
better protection against conformational changes compared to lower values.  However, 
combining 10% sucrose with 15% mannitol displayed the most promising outcome in 
delaying transition midpoint Tm (Table 5), an additive effect frequently previously 
observed with protein formulations.43,44,46 
      In conclusion, the physical stability of Consensus G11.4 VLPs was characterized in 
terms of secondary and tertiary structures as well as its colloidal stability. The thermal 
stability of Consensus G11.4 VLPs was shown to be pH dependent. Based on these 
results, it appears that VLPs are most stable around pH 5-6, and below ≈ 60oC. From 
excipients screening studies, it is shown that the combination of 15% mannitol and 10% 
sucrose yields VLPs with the highest conformational stability.             
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Section C 
Adsorption of Norwalk and Consensus G11.4 VLPs to Aluminum Salts – 
Binding isotherm and Front Face Fluorescence Studies 
 
Overview: 
        Since the introduction of potash alum (aluminum potassium sulphate) by Glenny 
and coworkers in 1926, Aluminum salts have been vital components of vaccine 
formulation, especially with those antigens that lack endogenous adjuvants (e.g. 
VLPs).47,48 Aluminum salt adjuvants, highly charged molecules, help low potency 
antigens to elicit a stronger immune response through a variety of proposed mechanisms. 
For half a century after they were introduced, aluminum salts adjuvants theorized 
mechanism of action (MOA) was attributed to a depot effect.49 However, in the last 
decade many hypotheses have been introduced with regard of their MOA including: 
activation of the innate immune system and induction of NOD-like receptor (NLR) 
family, through the pyrin domain containing 3 (NLRP3) inflammasomes among many 
others. 50-51 A definitive explanation on how these adjuvants stimulate the immune system 
is yet to be elucidated. The fact that Aluminum hydroxide (Alhydrogel®) and aluminum 
phosphate (Adjuphos®) possess both high safety and efficacy profiles made them widely 
used as commercial human vaccine adjuvants.52 Although contradicted recently53,54, the 
main dogma in adjuvant Induction of immune response was thought to be achieved by 
increasing the adsorption of antigen to the adjuvant surface.55 Many forces attribute to 
this adsorption, ranging from electrostatic interaction and hydrogen bonding to van der 
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Waals forces and hydrophobic interactions between antigens and adjuvants.56 The 
objective of this section is to construct binding isotherms of Norwalk-VLPs and 
Consensus G11.4 VLPs to aluminum salt adjuvants (Alhydrogel® and Adjuphos®) and 
to monitor structural changes associated with Norwalk and Consensus G11.4 VLP when 
bound to adjuvants using Front Face Fluorescence Spectroscopy. It is hoped that these 
results will aid in the final construction of efficacious formulations. 
Materials and Methods: 
        Based on structural characterization studies and the empirical phase diagram 
reported previously in section A, the buffer of choice for conducting preliminary binding 
isotherm studies was 10 mM imidazole, pH 7.5 containing 0.15M NaCl. Ligocyte 
Pharmaceuticals provided both NV-VLPs and Consensus G11.4 VLPs. Stock NV-VLP 
(Lot 45.06007.1) and Consensus G11.4VLP (Ligo 277.003.1) solutions were used for the 
binding isotherm studies. For front face fluorescence studies, VLP samples (Lot number 
NV-VLP M7VP1 and G11.4C Consensus CM3 dated 10Nov08) in 20 mM Histidine 
buffer, pH 6.5 + 0.15M NaCl were used. Concentrations of the VLPs were determined 
spectrophotometrically from their respective molar extinction coefficients (280 nm, of 
0.852 ml mg-1 cm-1 for NV-VLP and 280 nm, of 0.921 ml mg-1 cm-1 for Consensus 
G11.4 VLP). Adjuphos (batch number 9039) and Alhydrogel (batch number 4102) 
manufactured by Brenntag Biosector, Denmark were purchased from E.M. Sergeant Pulp 
& Chemical Co., Inc., Clifton, NJ. The concentration of stock Adjuphos and Alhydrogel 
were 4.8 mg/ml and 10.1 mg/ml, respectively.  
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Construction of Binding isotherms of Norwalk-VLP and Consensus G11.4 VLP to Alhydrogel 
and Adjuphos: 
        The binding assay was performed by adding increasing amounts of VLPs to a fixed 
amount of Alhydrogel (0.5 mg/ml) and Adjuphos (0.5 mg/ml) in 1.5 ml microfuge tubes. 
The final sample volume in each tube was 200 µl. The samples were mixed by gentle 
360o rotation at 4oC for 1 hour and then centrifuged at 14,000 rpm for 1 min. It was found 
that equilibrium (maximum binding) was reached by this procedure. The amount of 
unbound VLPs was measured by monitoring the A280 nm of the supernatants. All 
measurements were done in triplicate. 
 
Front Face Fluorescence Spectroscopy:  
 
        Fluorescence spectroscopy employing front face sampling geometry was used to 
probe changes in the tertiary structure of the VLPs as a function of temperature for both 
Norwalk and Consensus G11.4 VLP in solution, as well as adsorbed to the aluminum 
hydroxide adjuvant with and without the excipients selected earlier (section A). For all 
studies, a VLP concentration of 0.1 mg/ml was used. Sample solutions were prepared in 
triangular fluorescence quartz cuvettes by combining the aluminum salt (alhydrogel) 
suspension with an appropriate volume of 20 mM Histidine buffer, pH 6.5 + 0.15M 
NaCl, such that the final calculated aluminum concentration was 1.7 mg/ml in the 
absence and presence of 0.1 mg/ml VLP in a total volume of 2 ml. The concentration of 
 24 
aluminum was determined from the data provided by the supplier in the lot specification 
sheet.  
        Samples containing adjuvant were allowed to settle in the cuvettes overnight at 4°C. 
Emission spectra were recorded from 300 to 400 nm using a spectrofluorometer equipped 
with a Peltier thermostated cuvette holder (Photon Technologies International, 
Lawrenceville, NJ) employing an excitation wavelength of 295 nm (>95% Trp emission). 
Data were collected every 1 nm at a scanning rate of 1 nm/s. Emission spectra were 
obtained every 2.5 °C from 10 to 85°C with 300 seconds of thermal equilibration at each 
temperature. The data were processed using Origin version 7.0 software. A buffer 
baseline was subtracted from each raw emission spectrum.  
        Peak positions of the emission spectra were obtained using a “center of spectral 
mass” method (described in section A) using Origin 7.0 software. The actual peak 
positions are approximately 10-14 nm shifted from their actual values but the method 
does accurately reflect changes in the peak positions. 
Results and discussion: 
 
Binding isotherms of Norwalk-VLP and Consensus G11.4 VLP to Alhydrogel and Adjuphos: 
 
        Binding isotherm plots of VLP concentration with Alhydrogel are shown in Figure 
9A. It is evident that both NV-VLP as well as Consensus VLP bind tightly to Alhydrogel. 
In the case of the consensus VLP, saturation began to be approached after 0.8 mg/ml but 
was not reached saturation was also not obtained for NV-. For the NV-VLP, saturation 
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was not obtained because the stock concentration of NV-VLP was 1.07 mg/ml and thus 
measurements could not be carried out beyond 1.0 mg/ml.  Under the conditions 
examined by us, both NV-VLP and Consensus VLP were strongly bound to the 
Aluminum hydroxide adjuvant.  
         Adsorption isotherms of NV-VLP and Consensus-VLP to Adjuphos do not show 
any appreciable binding as shown in the plots (Figure 9B). NV-VLP and Consensus 
G11.4 VLP have theoretical acidic pI values of 5.64 and 5.61, respectively (determined 
from the Expasy Protparam server). Alhydrogel, being a basic particulate salt with a point 
of zero charge of 11 was shown to have a stronger binding affinity for both of the VLPs 
than Adjuphos.57 This suggests that electrostatic interactions may play a significant role 
in adsorption of the VLPs to the surface of aluminum hydroxide. 
        Since both the VLPs bind alhydrogel strongly, the extent of tertiary structural 
changes associated with Norwalk and Consensus G11.4 VLP when adsorbed to 
alhydrogel was monitored.  
 
Structural changes associated with Norwalk and Consensus G11.4 VLP when bound to 
Alhydrogel using Front Face Fluorescence Spectroscopy: 
        Shown in Figures 10A and B are the tertiary structural changes as determined by 
front face fluorescence spectroscopy for the Norwalk and Consensus G11.4 VLPs alone 
and when adsorbed to Alhydrogel in the absence and presence of stabilizers. Figure 
10(A) shows that at 10oC the tryptophan peak position of NV-VLP is approximately 342 
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nm (as calculated by the center of spectral mass method). With increases in temperature, 
the peak position gradually increases manifesting a transition midpoint (Tm) around 
64oC. In the presence of alhydrogel, although the initial peak position appeared to be 
slightly higher at low temperatures (344 nm) compared to that of NV-VLP alone, the Tm 
values are approximately 4-5oC greater in presence of alhydrogel ± selected excipients. 
Consensus G11.4 VLPs appear to be slightly more stable than NV-VLP alone because at 
low temperatures the tryptophan peak position is around 339 nm (Figure 10B). In the 
presence of alhydrogel, however, there was no significant change in the Tm values, in the 
presence of excipients (10% sucrose, 15% mannitol and a combination of both) although 
the VLP seems to be better stabilized as evident from the shift in Tm to higher 




        Aluminum hydroxide particles possess needle-like or fibril morphology, with a 
diameter of approximately 2 mm with a high surface area.58,59 The large surface area 
provides excellent adsorptive capability for protein antigens. Electrostatic forces often 
play a dominant role during alhydrogel binding to proteins although hydrophobic 
interactions also partially contribute to the adsorption of proteins to aluminum hydroxide 
gel. The pI of Consensus G11.4 VLP is 5.61 and that for NV-VLP is 5.64. Thus both the 
VLPs tend to bind to alhydrogel which is a basic salt particulate, presumably involving 
electrostatic forces at least to some extent. NV-VLP seems to be better stabilized in the 
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presence of alhydrogel alone compared to Consensus G11.4 VLP as evident from an 
increase in its melting temperature by 4oC. In the presence of excipients, the melting 
temperature for the adsorbed NV-VLP does not change to a detectable extent. In contrast, 
the Consensus G11.4 VLP shows better stability in the presence of excipients when 
adsorbed to Alhydrogel.  
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Table 1: Transition midpoint (Tm) values for Consensus G11.4 VLP at different pH values 





















pH Tm(C°) ± SD 
3 72.23 ± 0.37  
4 74.72 ± 0.66 
5 74.87 ± 0.31 
6 78.52 ± 0.57 
7 indecisive  
8 indecisive  
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 Table 2: Transition midpoint (Tm) values for Consensus G11.4 VLP at different pH values obtained from 
























3 54.6 ±0.36 
4 61.5±0.64  
5 64.6 ±0.45 
6 64.8±0.38  
7 61.2±0.25  
8 57.0±0.28  
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Table 3: Onset Temperature of aggregation (Tonset) values for Consensus G11.4 VLP at different pH 































Table 4: Percentage inhibition of aggregation of consensus G11.4 VLP in the absence and 
presence of different excipients. Compounds, which inhibit aggregation, have positive % of 
aggregation values and those, which accelerate aggregation, have negative % of aggregation 
values. The average % error is of the order of ±5%. 
 
+Sodium Citrate 0.2M 100 
+Trehalose 20% 100 
+Dextrose  20% 100 
+Glycerol  15%  98 
+Lysine 0.3M 94 
+Sucrose 20% 91 
+Mannitol 10% 90 
+Treh 15% 15% 87 
+Treh 10% 10% 86 
+Glutamic Acid 0.15 86 
+Sorbitol 20% 82 
+sod cit 0.1M 0.1M 76 
+sod cit 0.05M 0.05M 74 
+Glycerol 10% 10% 74 
+Glycine 0.3M 71 
+Malic Acid 0.15M 66 
+Proline 0.3M 62 
+2-OH propyl g-CD 10% 57 
+Arginine 0.3M 53 
+Lactose 20% 52 
Consensus VLP ± Excipients Concentration %Inhibition of Aggregation 
Consensus VLP only 0.1 mg/ml 100 
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+2-OH propyl g-CD 5.00% 28 
+Arginine 0.15M 26 
+Aspartic Acid 0.075M 24 
+2-OH propyl b-CD 10% 21 
+Glutamic Acid 0.05M 16 
+Glutamic Acid 0.1M 7 
+Calcium Chloride 0.015M 7 
+Arginine 0.1M 1 
+Dietanolamine 0.3M -4 
+Brij 35 30% (w/v) 0.10% -5 
+g-CD 2.50% -7 
+Lys 0.1 M 0.1M -7 
+Lactic Acid 85% 0.15M -11 
+Lys 0.15M 0.15M -13 
+a Cyclodextrin 2.5% -14 
+Histidine 0.3M -18 
+Tween 20 0.10% -26 
+Tween 80 0.10% -28 
+Guanidine-HCl 0.3M -32 
+Pluronic F-68 0.10% -32 
+Dextran Sulfate 0.0075 mM -76 
+Gelatin 5.0% na 
+Ascorbic acid 0.15M na 





Table 5:  Transition midpoints (Tm) and shifts in the Tm values observed for Consensus G11.4 














Excipients Tm(°C) Tm Shfit (°C) 
None  65.44±0.11 None 
+15%Treh 65.61±0.10 None 
+15%glycerol 65.6±0.14 None 
+10%gly+10%treh 65.37±0.12 None 
+0.3M arg 62.84±0.20 -2.60 
+20%mannitol 68.35±0.09 +2.91 
+15%mannitol 67.83±0.081 +2.39 
+20%sucrose 67.47±0.12 +2.03 
+15%suc 67.16±0.12 +1.72 
+10%man+10%suc 67.92±0.08 +2.48 
+10%man+15%suc 67.88±0.09 +2.44 
+10%suc 66.12±0.12 +0.68 
+10%man 67.14±0.14 +1.7 
+10%suc+15%man 69.72±0.13 +4.28 
+5%suc+5%man 65.93±0.11 +0.49 
+10%suc+5%man 67.44±0.13 +2 
+5%suc+10%man 67.16±0.15 +1.72 
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Table 6: Average Tm (midpoint of transition) values of norovirus VLPs in solution and when 
adsorbed to alhydrogel in absence and presence of stabilizers. (n=2). Tm values are determined 
by using the non-linear curve fit program of Origin 7.0 software. 
 
Virus-like Particle Adjuvant (+/- excipients) Tm (oC)±S.D. 
     NV-VLP Without alhydrogel                   64.0oC±0.34 
      With alhydrogel                   68.2oC±0.14 
 With alhydrogel+10% sucrose                   68.7oC±0.23 
 With alhydrogel+15% mannitol                   68.25oC±0.23 
 With alhydogel+10%sucrose+15% 
mannitol 
                  69.9oC±0.21 
Consensus G11.4 VLP Without alhydrogel                   63.98oC±0.49 
 With alhydrogel                   63.79oC±0.26 
 With alhydrogel+10%sucrose                   69.18oC±0.16 
 With alhydrogel+15%mannitol                   69.81oC±0.16 
 With 
alhydrogel+10%sucrose+15%mannitol 





















































































































































































































































































































































































































































A) Tryptophan peak position changes of consensus VLP as a function of pH and temperature (n=2). 



































































































































Figure 5: ANS extrinsic fluorescence intensity changes of the Consensus G11.4 VLP as a 
function of pH and temperature (n=2). 
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 Figure 6: Empirical Phase Diagram of Consensus G11.4 VLP based on data from 
circular dichroism, tryptophan peak position changes, trytophan fluorescence intensity changes, 













































































































Figure 7: Aggregation kinetics of Consensus G11.4 VLP in the presence of selected excipients. VLP (0.1 
mg/ml) in 20mM isotonic citrate phosphate buffer, pH 5.0 was incubated in the presence and absence of 
excipients at 60°C for 1 hour and the scattering intensity was monitored by measuring the optical density 
(OD at 350nm) every 5 min.(n=2) (A)VLP+excipients which inhibit the aggregation of VLP (B) 
VLP+excipients which do not inhibit aggregation of VLP 
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 0.1 mg/ml VLP
 +10% mannitol, 10% sucrose
 +10% mannitol, 15% sucrose
 +10% sucrose
 +10% sucrose, 15% mannitol
 +5% sucrose, 5% mannitol
 +10% sucrose, 5% mannitol
 +5% sucrose, 10% mannitol
 
 Figure 8(A, B): Tryptophan emission peak position as a function of pH and temperature. 
VLP solutions in the presence of selected excipients in 20 mM Histidine buffer, pH 6.5+0.15M 
NaCl were heated from 10 to 85 °C, and the fluorescence emission maxima were monitored upon 
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 NV-VLP+Alhydrogel+10 % sucrose + 15 % mannitol
 NV-VLP+Alhydrogel+10 % sucrose
 NV-VLP+Alhydrogel+ 15 % mannitol
 
 Figure 10(A): Tryptophan peak position changes determined by front face fluorescence 
spectroscopy for NV-VLP in solution and when adsorbed to alhydrogel in the absence and 
presence of selected excipients. 




























 G11.4VLP+alhydrogel+10 % sucrose
 G11.4VLP+alhydrogel+15 % mannitol




         Figure 10(B): Tryptophan peak position changes determined by front face fluorescence 
spectroscopy for Consensus G11.4-VLP in solution and when adsorbed to alhydrogel in the 
absence and presence of selected excipients. 
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